Pay in 4 interest-free payments of $7.23 Learn more
Ships within 48 hours · Estimated delivery Oct 6 - Oct 11
Its linked to lower dementia risk
Adverse Reactions in Clinical Trials in Adults with Obesity or Overweight for Weight Reduction WEGOVY 2.4 mg Subcutaneous Injection Weekly Dosage WEGOVY was evaluated for safety in 3 randomized, double-blind, placebo-controlled trials that included 2,116 adult patients with obesity or overweight treated with 2.4 mg WEGOVY injection for up to 68 weeks and a 7-week off-drug follow-up period [see Clinical Studies (14.2)]
Warfarin and other vitamin K antagonist anticoagulants may require more frequent monitoring when used concurrently with this medication
The drug has been subjected to a Class I recall, indicating that using the mislabeled drug can lead to serious health effects or even death
US$ 21.82
.png.jpg)
US$ 28.61
US$ 23.22
US$ 22.96
